Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine.

Anne Mahringer, Shirin Karamustafa, Daniel Martin Klotz, Stefan Kahl, V. Badireenath Konkimalla, Yi‐Fen Wang, Junsong Wang, Haiyang Liu, Herbert Boechzelt, Xiao‐Jiang Hao, Rudolf Bauer, Gert Fricker, Thomas EfferthPubMed 2010

Abstract

The blood-brain barrier (BBB) is a key determinant for drug transport through brain vessels. It restricts the pharmacological efficacy in numerous neurological diseases, including brain tumors. A major functional constituent of BBB is P-glycoprotein, which is also a major obstacle for effective chemotherapy of brain tumors. An appealing strategy is to selectively modulate BBB function using P-glycoprotein inhibitors. We assessed 57 chemically defined compounds derived from medicinal plants used in traditional Chinese medicine for their potential to inhibit P-glycoprotein. Nine phytochemicals inhibited P-glycoprotein in porcine brain capillary endothelial cells (PBCECs) and multidrug-resistant CEM/ADR5000 cells as shown by a calcein fluorescence assay. The cytotoxicity of the 57 phytochemicals was measured by a growth inhibition assay. Seven compounds inhibiting P-glycoprotein at lower doses were cytotoxic to drug-sensitive parental CCRF-CEM cells at higher doses. Of them, five were not cross-resistant to CEM/ADR5000 cells (baicalein, bufalin, glybomine B, deoxyserofendic acid, and shogaol). Bufalin was chosen as a lead compound. Of a further six bufalin-related compounds, scillarenin showed improved features in comparison to bufalin. It was cytotoxic to cancer cells at a nanomolar range. COMPARE and hierarchical cluster analyses of microarray-based mRNA expression were used to investigate determinants of sensitivity or resistance of the bufalin-related compounds downstream of P-glycoprotein. CEM/ADR5000 cells were not cross-resistant, but were collaterally sensitive towards scillarenin. Finally, scillarenin inhibited P-glycoprotein in PBCECs. Taken together, these data show that scillarenin is a potential novel candidate for P-glycoprotein inhibition at BBB, and, thereby, may improve the efficacy of therapy regimens in treating brain diseases.
BibTeX
@inproceedings{mahringer2010inhibition,
  author = {Anne Mahringer and Shirin Karamustafa and Daniel Martin Klotz and Stefan Kahl and V. Badireenath Konkimalla and Yi‐Fen Wang and Junsong Wang and Haiyang Liu and Herbert Boechzelt and Xiao‐Jiang Hao and Rudolf Bauer and Gert Fricker and Thomas Efferth},
  title = {{Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine.}},
  booktitle = {PubMed},
  year = {2010},
}

Loading related content...

Figure